Literature DB >> 12143876

Antiangiogenic therapy and p53.

Timothy Browder1, Judah Folkman, Philip Hahnfeldt, John Heymach, Lynn Hlatky, Mark Kieran, Michael S Rogers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12143876

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  4 in total

Review 1.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

2.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

Review 3.  Anti-angiogenic therapy in pediatric neuro-oncology.

Authors:  Mark W Kieran
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

4.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.